Alzheimer' s disease: From brain lesions to new drugs;La maladie d'Alzheimer: Des lésions cérébrales aux perspectives thérapeutiques

Bulletin de l'Academie Nationale de Medecine

Volumn 192, Issue 2, 2008, Pages 363-380

  Forette, Françoise ^a   Hauw, Jean Jacques ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b NONE

Author keywords

Alzheimer disease drug therapy

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMINO ACID RECEPTOR BLOCKING AGENT; AMYLOID PRECURSOR PROTEIN; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; CHOLINESTERASE INHIBITOR; ENZYME INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MAPT PROTEIN, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT; NOOTROPIC AGENT; TAU PROTEIN;

ALZHEIMER DISEASE; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG SCREENING; ESTROGEN THERAPY; GENE THERAPY; HUMAN; IMMUNOTHERAPY; METABOLISM; PATHOLOGY; REVIEW; STEM CELL TRANSPLANTATION;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN PRECURSOR; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; ESTROGEN REPLACEMENT THERAPY; EXCITATORY AMINO ACID ANTAGONISTS; GENE THERAPY; HUMANS; IMMUNOTHERAPY; NOOTROPIC AGENTS; STEM CELL TRANSPLANTATION; TAU PROTEINS;

EID: 55949107417     PISSN: 00014079     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-4079(19)32836-5     Document Type: Article

References (87)

1. BLENNOW K., DE LEON M.J. -Alzheimer's disease. The Lancet, 2007, 368, 387-403.
2. KLAFKI H.W., STAUFENBIEL M., KORNHUBER J., WiLTFANG J. -Therapeutic approaches to Alzheimer's disease. Brain, 2006, 129, 2840-55.
3. DAVIS J.B., BOUNTRA C., RICHARDSON J. -Perspectives of Alzheimer'disease treatments. In : Dementias, Handbook of Clinical Neurology, Vol.89, Eds C Duyckaerts et I Litvan, Elsevier BV, sous presse.
4. PALOP JJ., CHIN J., MUCKE L. -A network dysfunction perspective on neurodegenerative diseases. Nature. 2006, 443, 768-773
5. LLEDO P.M., GHEUSI G. -Neurogénèse adulte : aspects fondamentaux et potentiels thérapeutiques. Bull Acad Natl Med. 2006, 190, 385-400.
6. MCGEER E.B., MCGEER P.L. -Inflammatory processes in Alzheimer's disease. Prog Neuropsy- chopharmacol. Biol Psychiatry, 2003, 27, 741-749
7. SZEKELY C.A., THORNE J.E., ZANDI P.P. -Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease : a systematic review. Neuroepidemiology, 2004, 23, 159-169
8. SALPETER S.R, GREGOR P., ORMISTON T.M., WHITLOCK R., RAINA P., THABANE L., TOPOL EJ. - Meta-analysis : cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med. 2006; 119: 552-559
9. AISEN P.S., SCHÄFER K. A., GRUNDMAN M. et al. -Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression : a randomized controlled trial. JAMA, 2003,289,2819-26.
10. JICK H., ZORNBERG G.L., JICK S.S., SESHADRI S., DRACHMAN D.A. -Statins and the risk of dementia. Lancet, 2000, 356, 1627-1631
11. WOLOZIN B. -Cholesterol and the biology of Alzheimer's disease. Neuron, 2004, 41, 7-10.
12. Li G., LARSON E.B., SONNEN J.A., SHOFER J.B., PÉTRIE B.C., SCHANTZ A. et al.-Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease Neurology, 2007,69, 878-885.
13. REFOLO L., MALESTER B., LAFRANCOIS J., BRYANT-THOMAS T., WANG R. et coll. -Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis., 2000, 7, 321-331.
14. SHEPERD J., BLAUW G.J., MURPHY M.B. et al. -Pravastatin in elderly individuals at risk of vascular disease (PROSPER) : a randomised controlled trial. Lancet, 2000, 360, 1623-1630
15. Heart Protection Study Collaborative Group (2002) MRC/BHF. Heart protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals : a randomised placebocontrolled trial. Lancet, 2002, 360, 7-22.
16. Li G., HIGDON R., KUKULL W.A. et al. -Statin therapy and risk of dementia in the elderly : a community-based prospective cohort study. Neurology, 2004, 63, 1624-1628
17. WOLOZIN B., MANGER J., BRYANT R., CORDY J., GREEN R.C., MCKEE A. -Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta. Neurol. Scand. Suppl. 2006, 185, 63-70.
18. LEBLANC E.S., JANOWSKY J., CHAN B.K., NELSON H.D. -Hormone Replacement therapy and cognition. Systematic review and meta-analysis. JAMA, 2001, 285,1489-1499
19. HOGERVORST E., YAFFE K., RICHARDS M., HUPPERT F. -Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane database Syst. Rev. 2002, 3, CD003799.
20. ROCCA W.A., BOWER J.H., MARAGANORE D.M., AHLSKOG J.E., GROSSARDT B.R., DE ANDRADE M., MELTON L.H. -Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology, 2007, 69, 1074-1083.
21. MULNARD R.A., COTMAN C.W., KULLER I. et al. -Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease : a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA, 2000, 283, 1007-1015
22. SHUMAKER S.A., LEGAULT C., KULLER L. et al.-Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women : Women Health Initiative Memory Study. JAMA, 2004, 291, 2947-2958
23. ENGELHART MJ., GEERLINGS M.I., RUITENBERG A. et al.-Dietary intake of antioxydants and risk of Alzheimer disease. JAMA, 2004, 287, 3223-3229
24. MORRIS M.C., EVANS D.A., BIENIAS J.L. et al.-Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA, 2002, 287, 3230-3237
25. SANO M., ERNESTO C., THOMAS R.G. et al. -A controlled trial of selegiline, alpha-tocopherol or both as a treatment for Alzheimer's disease. N. Eng. J. Med., 1997, 336, 1216-1222
26. PETERSEN R.G, THOMAS R.G., GRUNDMAN M. et al. -Vitamin E and donezepil for the treatment of mild cognitive impairment. N Eng. J. Med., 2005, 352, 2379-2388
27. SKOOG I., LERNFELT B., LANDAHL S. et al. -15-year longitudinal study of blood pressure and dementia. Lancet, 1996, 347, 1141-1145
28. HANON O., SEUX M.L, LENOIR H., RIGAUD A.S., FORETTE F. -Hypertension and dementia. Curr. Cardiol. Rep., 2003, 6, 435-440
29. FORETTE F., SEUX M.L., STAESSEN J.A. et al. -Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet, 1998, 552, 1347-1351
30. FORETTE F., SEUX M.L., STAESSEN J. et al.-The prevention of dementia with antihypertensive treatment : new evidence from the Systolic Hypertension in Europe (Syst-eur) study. Arch. Int. Med., 2002, 162, 2046-2052
31. TZOURIO C., ANDERSON C., CHAPMAN N. et al. -PROGRESS Collaborative Group. Effects of blood pressure lowering with Perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med., 2003, 163, 1069-1075
32. BIRKENHEGER W.H., FORETTE F., SEUX M.L. et al. -Blood pressure, cognitive functions, and prevention of dementia in older patients with hypertension. Arch. Int. Med. 2002, 161, 152.
33. HANON O., PÉQUIGNOT R., SEUX M.L. et al. -Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints. J. Hypertens., 2006, 1, 2101-2107
34. MORRIS M.C., EVANS D.A., BIENIAS J.L. et al. -Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol., 2003, 60, 940-946
35. BABERGER-GATEAU P., RAFFAITIN C., LETENNEUR L., BERR C., TZOURIO C., DARTIGUES J.F. - Alpérovitch A Dietary pattern and risk of dementia. The Three-City cohort study. Neurology, 2007, 69, 1921-1930.
36. SIMONSICK E.M. -Fitness and cognition : encouraging findings and methodological considerations for future work. J. Am. Geriatr. Soc., 2003, 51, 570-571
37. VERGHESE J., LIPTON R.B., KATZ M.J. et al. -Leisure activities and the risk of dementia in the elderly. N. Engl. J. Med, 348, 2508-2516
38. COYLE J.T -Use it or lose it -Do effortful mental activities protect against dementia ? Ai Engl. J. Med., 2003, 348, 2489-2490
39. Luo Y., BOLON B., KAHN S. et al. -Mice deficient in BACE1, The Alzheimer beta-secretase, have normal phénotype and abolished beta-amylo'id generation. Nat. Neurosci., 2001, 4, 231-232
40. HUSSAIN I., HAWKINS J., HARRISON D. et al. -Oral administration of a potent and selective non peptidic BACE1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid beta production in vivo. J. neurochem., 2007, 100, 802-809
41. HILLS I.D., VACCA IP. -Progress toward a practical BACE-1 Inhibitor. Curr. Opin Drug Discov. Devel., 2007, 4, 383-391
42. HULL M., BERGER M., HENEKA M. -Disease-modifying therapies in Alzheimer's disease : how far have we come ? Drugs, 2006, 66, 2075-2093
43. EVIN G., SERNEE M.F., MASTERS C.L. -Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease : propescts, limitations and strategies. CNS Drugs, 2006, 20, 351-372
44. PETIT A., BIHEL F., ALVES DA COSTA C., POURQUIE O., CHECLER F., KRAUS JL.-New protease inhibitors prevent gamma-secretase production of Abeta 40/42 without affecting Notch cleavage. Nat. Cell. Biol., 3, 507-511
45. SIEMERS E., SKINNER M., DEAN R.A. et al. -Safety, tolerability, and changes in amyloid beta concentration after administration of a gamma-secretase inhibitor in volunteers. Clin. Neuropharmacol., 2005, 28, 126-132
46. HOCK C., MADDALENA A., RASCHIG A., MÜLLER-SPAHN F., ESCHWEILER G. et coll. -Treatment with the selective muscarinic ml agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid, 2003, 10, 1-6.
47. ETCHEBERRIGARAY R., TAN M., DEWATCHTER I. et al. -Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc. Natl. Acad. Sci. USA, 2004, 101, 1141-1146
48. SCHENK D., BARBOUR R., DUNN W. et al. -Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse, Nature, 1999, 400, 173-177.
49. JANUS C., PEARSIN J., MCLAURIN J. et al. -A peptide immunisation reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature, 2000, 408, 979-982
50. MORGAN D., DIAMOND D.M., GOTTSCHALL P.E. et al. -Ab peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 2000, 408, 982-985
51. ORGOGOZO J.M., GILMAN S., DARTIGUES J.F. et al. -Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization, Neurology, 2003, 61, 46-54.
52. GILMAN S., KOLLER M., BLACK R.S. -Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 2005, 64, 1553-1562
53. Fox N.C, BLACK R.S., GILMAN S. et al. -Effects of beta immunization (AN 1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology, 2005, 64, 1563-1572
54. NiCOLL J.A., WILKINSON D., HOLMES C., MARKHAM H., WELLER CO. -Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide : a case report. Nat. Med., 2003, 9, 448-452
55. MASLIAH E., HANSEN L., ADAM A. et al. -Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology, 2005, 64, 129-131
56. HOCK C., KONIETZKO U., STREFFER J.R. -Antobodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neron, 2003, 38, 547-554
57. AGADJANYAN M.G., GHOCHIKIAN A., PETRUSHINA I. et al. -Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beat amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol., 2005, 174, 1580-1586
58. FILLIT H. -Intravenous immunoglobulins for Alzheimer's disease. The Lancet Neurology, 2004, 3, 704.
59. DODEL R.C., Du Y., DEPBOYLU C et al. -Intravenous immunoglobulin containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry, 2004, 75, 1472-1514
60. HAASS C., SELKOE D.J. -Soluble protein oligomers in neurodegeneration : lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol., 2007, 8, 101-112
61. VAN HORSSEN J., WESSELING P., VAN DEN HEUVEL L.P. et al.- Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol. 2003, 2, 482-492
62. RiTCfflE C.W., BUSH A.I., MACKINNON A. ET al. -Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease : a pilot phase 2 clinical trial, Arch. Neurol., 2003, 60, 1685-1691.
63. BUÉE L., DELACOURTE A.-Tauopathie et maladie ď Alzhemer, un processus dégénératif à part entière. Psychol. Neuropsychiatr. Vieil., 2006, 4, 1-12.
64. DELACOURTE A., BUÉE L. -Animal models of Alzheimer's disease : A road full of pitfalls. Psychol. Neuropsychiatr. Vieil., 2005, 3, 261-270.
65. BUÉE L., BUSSIÈRE T., BUÉE-SCHERRER V., DELACOURTE A., HOF P.R. -Tau proteins isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Rev., 2000, 33, 95-130.
66. ZHONG J., LEE WH. -Lithium : a novel treatment for Alzheimer's disease ? Expert Opin. Drug Saf., 2007, 6, 375-383
67. CHOHAN M.O., KHATOON S., IQBAL I.G., IQBAL K. -Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine. FEBS Lett. 2006, 580, 3973-3979
68. PICKHARDT M., GAZOVA Z., VON BERGEN M. et al. -Antrhaquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J. Biol. Chem., 2005,280, 3628-3635
69. LEE H.G., PERRY G., MOREIRA P.L. ET al. -Tau phosphorylation in Alzheimer's disease : pathogen or protector ? Trends Mol. Med., 2005, 11, 164-169
70. WEST M.J., COLEMAN P.D., FLOOD D.G., TRONCOSO J.C. -Differences in the pattern of hippocampal neuronal loss in normal aging and Alzheimer disease Lancet, 1994, 344, 769-772.
71. TUSZYNSKI M.H., THAL L., PAY M., SALMON D.P., U.H.S., BAKAY R., PATEL P. et al. -A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med., 2005,11, 551-555.
72. TUSZYNSKI M.H. -Nerve growth factor gene therapy in Alzheimer disease. Alzheimer Dis. Assoc Disord., 2007, 27, 179-189.
73. ALLEN S.J., DAWBARN D. -Clinical relevance of the neurotrophins and their receptors. Clin. Sci. (Lond), 2006, 110, 175-191
74. ZIABREVA I., PERRY E., PERRY R., MINGER S.L., EKONOMOU A., PRZYBORSKI S., BALLARD C - Altered neurogenesis in Alzheimer's disease. J. Psychosom. Res., 2006, 61, 311-316
75. BRINTON R.D., WANG J.M. -Preclinical analyses of the therapeutic potential of allopregnanolone to promote neurogenesis in vitro and in vivo in transgenic mouse model of Alzheimer's disease. Curr. Alzheimer Res., 2006, 3, 11-17
76. CHEN H., TUNG Y.C, LI B., IQBAL K., GRUNDKE-IQBAL I. -Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. Neurobiol. Aging. 2007, 28, 1148-1162
77. WISNIEWSKI T., SIGURDSSON E.M. -Therapeutic approaches for prion and Alzheimer's diseases. FEBS J., 2007, 274, 3784-3798
78. WOODS J., SNAPE M., SMITH M.A. -The cell cycle hypothesis of Alzheimer's disease : suggestions for drug development. Biochim. Biophys Acta., 2007, 1772, 503-508
79. BOWMAN G.L., KAYE J.A., MOORE M., WAICHUNAS B.A., CARLSON N.E., QUINN JF. - Blood-brain barrier impairment in Alzheimer disease : stability and functional significance. Neurology, 2007, 68, 1809-1814.
80. DESAI B.S., MONAHAN AJ., CARVEY P.M., HENDEY B. -Blood-brain barrier pathology in Alzheimer's and Parkinson's disease : implications for drug therapy. Cell Transplant., 2007,16, 285-299
81. BOWLER J.V., MUNOZ D.G., MERSKEY H., HACHTNSKI V. -Fallacies in the pathological confirmation of the diagnosis of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry, 1988,64, 18-24.
82. Neuropathology Group study of the Medical Research Council Cognitive Function and Aged study (MRC CFAS) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. The Lancet, 2001, 357, 168-175.
83. ZEKRY D., DUYCKAERTS C., BELMIN J., GEOFFRE C., MOULIAS R., HAUW JJ. -Alzheimer's disease and brain infarcts in the elderly. Agreement with neuropathology. J. Neurol, 2002, 249, 1529-1534.
84. THAL L.J., CARTA A., DOODY R., LEBER P., MOHS R., SCHNEIDER L., SHIMOHAMA S., SILBER C - Prevention protocols for Alzheimer disease : position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis. Assoc. Disord, 1997, 11(suppl 3), 46-49.
85. BROOKMEYER R. et al. -Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health., 1998, 88, 1337-1342.
86. CUMMINGS J.L., DOODY R., CLARK C. -Disease-modifying therapies for Alzheimer disease. Challenge to early intervention. Neurology, 2007, 69, 1622-1634.
87. FELDMAN H.H., JACOVA C. -Primary prevention and delay of onset of AD/dementia. Can. J. Neurol. Sci., 2007, 34 S, 84-89.